July 10, 2024
Tag: Natalie Grover
June 21, 2024
WGEM: Last chance: How CAR T-Cell therapy saved John
December 8, 2023
CAR-T therapy helps patient beat cancer
When standard treatment didn’t work to treat his diffuse large B-cell lymphoma, John Bell found successful treatment with CAR-T therapy.
December 8, 2023
UNC researchers present latest findings at American Society of Hematology Annual Meeting
Researchers from UNC Lineberger and UNC will present findings from studies, speak at scientific symposia and lead educational sessions at the 65th American Society of Hematology Annual Meeting.
July 25, 2023
Questions and answers about CAR-T therapy
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
May 23, 2023
Scientific retreat underscores impact and promise of cancer center’s research
UNC Lineberger's annual scientific retreat brought together faculty, staff and trainees to learn about the latest research at the cancer center.
March 4, 2021
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
January 14, 2020
Dittus and colleagues write the book on rare lymphomas
UNC Lineberger’s Christopher Dittus, DO, MPH, assistant professor of medicine at UNC School of Medicine, is the editor of a new book that provides a comprehensive review of how to diagnose and manage rare lymphomas, with a focus on novel treatment approaches. UNC Lineberger faculty and trainees contributed chapters to the volume. “Novel Therapeutics for …
December 3, 2018
Study shows promise for fighting relapsed blood cancer with CAR-T immunotherapy, chemotherapy
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.